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Background: Endometrial cancer (EC) is a common female malignant cancer. The age of incidence has become
younger than before. If the diagnosis is during stage I, then the survival rate is about 90%. To date, there are no
specific tumor markers for endometrial cancer. We usually use serum CA125 to help in diagnosing it. However, a
serum biomarker CA125 greater than 35 U/ml is not useful in diagnosing EC at an early stage. Now, human
epididymis protein 4 (HE4) has been intensively studied, and has been described as a new marker for ovarian
cancer. The goal of this study was to evaluate the clinical value of serum HE4 in the diagnosis of endometrial
cancer by meta-analysis.
Methods: We used MEDLINE, EMBASE, Cochrane Library and CBM databases to search the literature. The
meta-analysis was performed by using Meta-Disc 1.4 software.
Results: All data we obtained showed that the major advantage of HE4 lies in its specificity in endometrial cancer
diagnosis. Its sensitivity in serum was not as high as expected. But this evidence is not enough.
Conclusions: Additional studies, particularly to evaluate HE4’s capability in identifying EC at an early stage, will be
needed.
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Endometrial cancer is a common female malignancy.
The incidence varies because of different lifestyles and
regions. In developed countries, the incidence rate is the
highest among female genital malignancies, and the age
of incidence has become younger than before. The prog-
nosis is closely related to the disease stage. If the diagno-
sis is during stage I, then the survival rate is about 90%.
There are no specific tumor markers for endometrial
cancer. CA125 was detected in 1983 by Bast et al. [1] as
the epithelial ovarian carcinoma antigen. It is a macro-
molecular polymer glycoprotein, expressed in body cav-
ity epithelial. Serum CA125 level is elevated in many
primary tumors, such as ovarian, endometrial, colorectal,
breast and lung cancers. It is also elevated in a number
of other conditions, including pregnancy, inflammation,
endometriosis, fibroids, benign ovarian cysts, cirrhosis
and abdominal surgery [2]. It can be detected in the* Correspondence: bjzhangzhy@sina.cn
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unless otherwise stated.blood, pleural effusion, ascites and amniotic fluid. So, as
a tumor marker, it has low sensitivity and specificity for
early diagnosis of endometrial carcinoma. Several au-
thors have found that higher serum CA125 levels corre-
lated with the extra uterine disease and advanced cases.
It is always used as a marker to evaluate prognosis and
recurrence in endometrial cancer. However,a CA125
level greater than 35 U/ml is not useful in diagnosing
early stages of endometrial cancer (EC).
It may be necessary to find other biomarkers for early
detection of endometrial cancer and for monitoring high
risk patients, such as those with severe obesity, diabetes,
Lynch syndrome (hereditary non-polyposis colorectal
cancer syndrome), PTEN gene defects or those given
tamoxifen therapy for breast cancer. New biomarkers
will also be used to guide treatment, monitor therapeutic
effect and predict recurrence. To date, human epididy-
mis protein 4 (HE4) has been intensively studied. It was
identified in the epithelium of the distal epididymis and
originally predicted to be a protease inhibitor involved
in sperm maturation [3]. Now it has been described as aal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Selection process for articles included in the meta-analysis.
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proved serum HE4 is elevated in all stages of endomet-
rial cancer and is more sensitive in early stage endomet-
rial cancer compared to CA125 [5].
The goal of this study was to evaluate the clinical value
of serum HE4 in the diagnosis of endometrial cancer by
meta-analysis.
Methods
Literature searches of MEDLINE, EMBASE, the Cochrane
Library databases and CBM were performed. Index words
included the medical subject headings (MeSH): endomet-
rial neoplasms and uterine neoplasms, and the following
text words: endometrium, endometrial, uterus, uterine,
cancer, carcinoma, HE4, WFDC2, human epididymis pro-
tein 4 and human epididymis-specific protein 4. Search
terms related to study design and publication type in-
cluded systematic review, clinical trial, meta-analysis, con-
trolled clinical trials and randomized controlled trials.
Reference lists of identified studies were scanned forTable 1 Summary data of the original studies
Author Country Year Type of study Patien
Moore RG et al. [5] USA 2008 prospective/retrospective 171
Zanotti L et al. [6] Italy 2012 retrospective 193(15
Angioli R et al. [7] Italy 2013 prospective 101(95
Omer Bet al. [8] Turkey 2013 prospective l 64(54 +
Bignotti E et al. [9] Italy 2011 prospective 138(10
Zhang, Ai-min et al. [10] China 2012 prospective 124
Total 791
Studies [6], [7], [8] and [9] included patients with different pathological types. The p
and [10] included people with uterine benign disease and had healthy people as co
FN, False Negative; FP, False Positive; SEN, Sensitivity; SPE, Specificity TN, True Negaadditional citations until no additional articles could be
identified.
Inclusion criteria were all papers with pathological
diagnosis and serum HE4 value. And the aim of these ar-
ticles was the role of serum HE4 in diagnosis of endo-
metrial cancer.
Reviews and papers without a serum HE4 test value
were excluded. Studies reporting insufficient data for the
construction of a two-by-two table were excluded from
the final analyses.Quality assessment
The methodological quality of each trial was evaluated
by the quality-assessment tool for diagnostic accuracy
studies (QUADAS-2). The quality of research was evalu-
ated independently by two reviewers, based on the fol-
lowing criteria: 1) the experiment has a pathological
diagnosis, 2) the inclusion criteria of the research were
clear, 3) statistics were appropriate, 4) the study cants Control Cut off (pmol/L) TP FP FN TN SEN SPE
156 / 78 8 93 148 46 95
2 + 41) 125 51 152 19 41 106 79 85
64 127 6 66 119 66 95
+ 6) 103 70 60 0 41 103 59 100
150 36 0 65 103 36 100
10) 94(60 + 34) 60 48 32 16 62 75 66
9 + 29) 76 / 92 4 46 72 67 95
206(97 + 109) / 51 10 73 196 41 95
760
athological types of patients in study [5] and study [10] are unclear. Studies [8]
ntrols. The controls of other studies are healthy.
tive; TP, True Positive.
Figure 2 Forest plots of sensitivity of HE4 for EC prediction. The red circles represent the sensitivity of one study; the black line shows its
confidence interval. If a study reported accuracy data for more than one cut-off, its results are included more than once.
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and 6) biases in the study were discussed.
Statistical analyses
The meta-analysis was performed by using Meta-Disc
1.4 software (The program has been developed by the
Unit of Clinical Biostatistics team of the Ramón y Cajal
Hospital in Madrid (Spain)). Analysis of heterogeneity
between studies was done using the χ2 test. If there was
no significant heterogeneity between studies (P > 0.1,
I2 ≤ 50%), the analysis was performed using a fixed-
effects model and analyzed bias to obtain sensitivity, spe-
cificity, positive predictive and negative predictive values.
If there was statistical heterogeneity among studies, the
analysis was performed using the random-effects model
(P ≤ 0.1, I2 > 50%).
Results
The search identified 34 potentially relevant papers
based on the search terms. A total of six studies met allFigure 3 Forest plots of specificity of HE4 for EC prediction. The red c
confidence interval. If a study reported accuracy data for more than one cuthe eligibility criteria for this review. The selection
process for articles included in the meta-analysis is
shown in Figure 1. Basic information on included studies
is shown in Table 1.
In the six trials there are one retrospective study [6],
four prospective studies and one study analyzed as hav-
ing either prospective or retrospective data [5].
In control groups, Angioli et al. [7] was the first to
enroll patients with benign uterine disease as controls.
Omer et al. [8] used patients with benign uterine dis-
ease and healthy women as controls. Moore et al. [5]
and Bignotti et al. [9] used postmenopausal healthy
women as controls in their studies. And also an art-
icle in Chinese used patients with benign uterine dis-
ease and healthy women as controls [10]. Moreover,
three studies evaluated the sensitivity of HE4 without
indicating a cut-off value [5,9,10]. And two other
studies reported data on two thresholds [6,7]. We
have included the two-by-two tables for all reported
thresholds.ircles represent the specificity of one study; the black line shows its
t-off, its results were included more than once.
Figure 4 Diagnostic odds ratio of HE4 for EC prediction. Heterogeneity existed among the study designs. Cochran-Q is 22.13 in diagnostic
odds ratio, P = 0.0024. Heterogeneity existed among the studies’ designs. Cochran-Q is 22.13 in diagnostic odds ratio, P = 0.0024.
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patient groups [6-9].
Meta-analysis
High levels of heterogeneity lay in both sensitivity (I2 = 92.9%)
and specificity (I2 = 93.1%). Forest plots of sensitivity and
specificity of HE4 for EC prediction were shown in
Figures 2 and 3. Mean estimates and their 95% CIs were:
sensitivity 0.594 (0.564 to 0.623), specificity 0.920 (0.901 to
0.936). A threshold effect existed (Spearman correlation
coefficient: 0.755, P-value = 0.031). The random-effects
model was used to pool estimates. And heterogeneity
existed among the study designs. Cochran-Q is 22.13 in a
diagnostic odds ratio, P = 0.0024 (Figure 4). The area
under the summary receiver operating-characteristic curveFigure 5 SROC of HE4 for EC prediction. Each circle represents each stu
of the circle. The regression summary receiver operating characteristic curv(SROC) was 0.8321 (Figure 5). The DOR (diagnostic odds
ratio) is 20.816 (11.434 to 37.896).
Meta-regression was used to investigate the potential
sources of heterogeneity. We found the control group
(healthy women or women with benign disease) and the
different pathological types of patients act as potential
sources of heterogeneity. We divided the studies into differ-
ent subgroups according to pathological types of patients
and whether they included people with uterine benign dis-
eases as controls. Then subgroup analysis was made and
heterogeneity was assessed in these subgroups (Table 2).
Discussion
Several reviews have been published in recent years
about using serum HE4 for the diagnosis of EC. Most ofdy in the meta-analyses. The size of each study is indicated by the size
es summarize the overall diagnostic accuracy.
Table 2 Effect of subgroups
Subgroup Studies SEN (95% CI) SPE (95% CI) DOR (95% CI) I2(%) P
Pathological types
of patients
Adenocarcinoma + other types 6 0.652 (0.618 to 0.685) 0.903 (0.877 to 0.925) 27.291 (11.011 to 67.640) 77.10 0.001
Unclear 2 0.437 (0.380 to 0.496) 0.950 (0.923 to 0.970) 14.524 (8.547 to 24.681) 0.00 0.817
Control Uterine benign
diseases + healthy
4 0.500 (0.449 to 0.551) 0.917 (0.889 to 0.940) 22.555 (5.473 to 92.943) 80.10 0.002
Healthy 4 0.646 (0.609 to 0.682) 0.923 (0.896 to 0.945) 23.426 (15.767 to 34.806) 3.50 0.375
Total 8 0.594 (0.564 to 0.623) 0.920 (0.901 to 0.936) 20.816 (11.434 to 37.896) 68.40 0.0024
The studies were divided into different subgroups according to the patients’ pathological types and different controls. DOR, Diagnostic odds ratio; SEN, Sensitivity;
SPE, Specificity.
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methods [11-14].
The result of our meta-analysis show that serum HE4
level could help predict the presence of EC based on
whether the area under the curve (AUC) was 0.8321.
HE4 showed sensitivity 0.594(0.564 to 0.623) and high
specificity 0.920(0.901 to 0.936). Therefore, the associ-
ated poor sensitivity of HE4 clearly limits its value in its
diagnosis of EC. This conclusion is similar to that of
Jacob et al. [15], in which the authors concluded the
major advantage of HE4 lies in its specificity and im-
proved detection of borderline tumors and early stage
ovarian and tubal cancers. They also showed that there
were no benefits from combining HE4 and CA125 as
ovarian tumor markers in a clinical setting [15].
However, due to the heterogeneity, the meta-analysis
results should be interpreted with caution. We used
meta-regression and found the control group (healthy
women or women with benign disease) and the different
pathological types of patients act as potential sources of
heterogeneity. We also noted that the overall diagnostic
accuracy of HE4 is more superior in healthy control
groups compared to control subjects with benign disease
(Table 2). The limitation of the present meta-analysis is
that there is no unified cutoff. The assay method
(ELISA, chemiluminescent micro particle immunoassay,
bead-based array system), and the patients’ status and
small samples also account for the lack of evidence to
support HE4 as a tumor marker for EC. Some studies
found that HE4 levels in healthy subjects are associated
with age and smoking status. Age-dependent reference
limits are suggested [14,16]. It is necessary to collect
more data to improve the research. And it would be es-
sential to define a specific normal range and cut-off
value for women of different ages, respectively.
Conclusion
This review showed that although we do have an esti-
mate of the test accuracy of serum HE4 for the diagnosis
of EC, we have not enough data to estimate its value in
clinical practice. It is necessary to get more data to im-
prove the quality of the research. Additional studies,particularly to evaluate HE4 role in endometrial cancer
staging and pathological types, are needed.
Abbreviations
CI: Confidence interval; DOR: Diagnostic odds ratio; EC: Endometrial cancer;
HE4: Human epididymis protein 4; SROC: summary receiver operating-
characteristic curve.
Competing interests
No conflict of interest exits in the submission of this manuscript, and
manuscript is approved by all authors for publication.
Authors’ contributions
All authors have contributed significantly and all authors are in agreement
concerning the content of the manuscript. YB and ZZ evaluated the
researches independently. YB drafted the manuscript. All authors read
and approved the final manuscript.
Received: 26 February 2014 Accepted: 9 May 2014
Published: 29 May 2014
References
1. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS,
Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC: A
radioimmunoassay using a monoclonal antibody to monitor the course
of epithelial ovarian cancer. N Engl J Med 1983, 309:883–887.
2. Aggarwal P, Kehoe S: Serum tumour markers in gynaecological cancers.
Maturitas 2010, 67:46–53.
3. Kirchhoff C: Molecular characterization of epididymal proteins. Rev Reprod
1998, 3:86–95.
4. Abdel-Azeez HA, Labib HA, Sharaf SM, Refai AN: HE4 and mesothelin: novel
biomarkers of ovarian carcinoma in patients with pelvic masses.
Asian Pac J Cancer Prev 2010, 11:111–116.
5. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO,
Bast RC Jr, Lu K: Utility of a novel serum tumor biomarker HE4 in patients
with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 2008,
110:196–201.
6. Zanotti L, Bignotti E, Calza S, Bandiera E, Ruggeri G, Galli C, Tognon G,
Ragnoli M, Romani C, Tassi RA, Caimi L, Odicino FE, Sartori E, Pecorelli S,
Ravaggi A: Human epididymis protein 4 as a serum marker for diagnosis
of endometrial carcinoma and prediction of clinical outcome. Clin Chem
Lab Med 2012, 50:2189–2198.
7. Angioli R, Plotti F, Capriglione S, Montera R, Damiani P, Ricciardi R, Aloisi A,
Luvero D, Cafa EV, Dugo N, Angelucci M, Benedetti-Panici P: The role of
novel biomarker HE4 in endometrial cancer: a case control prospective
study. Tumour Biol 2013, 34:571–576.
8. Omer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S, Gurdol F:
The diagnostic role of human epididymis protein 4 and serum
amyloid-A in early-stage endometrial cancer patients. Tumour Biol
2013, 34:2645–2650.
9. Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S, Bergamelli S,
Bandiera E, Tassi RA, Romani C, Todeschini P, Odicino FE, Facchetti F,
Pecorelli S, Ravaggi A: Diagnostic and prognostic impact of serum
HE4 detection in endometrial carcinoma patients. Br J Cancer 2011,
104:1418–1425.
Bie and Zhang World Journal of Surgical Oncology 2014, 12:169 Page 6 of 6
http://www.wjso.com/content/12/1/16910. Zhang AM, Zhang P: [Clinical value of combined detection of serum
human epididymal secretory protein E4 and CA(125) in the diagnosis of
endometrial carcinoma]. Zhonghua Fu Chan Ke Za Zhi 2012, 47:125–128.
11. Angioli R, Miranda A, Aloisi A, Montera R, Capriglione S, De CiccoNardone C,
Terranova C, Plotti F: A critical review on HE4 performance in endometrial
cancer: where are we now? Tumour Biol 2014, 35:881–887.
12. Plebani M, HE4 Study Group: HE4 in gynecological cancers: report of a
European investigators and experts meeting. Clin Chem Lab Med 2012,
50:2127–2136.
13. Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C,
Widschwendter A: HE4 is an independent prognostic marker in
endometrial cancer patients. Gynecol Oncol 2012, 126:186–191.
14. Galgano MT, Hampton GM, Frierson HF Jr: Comprehensive analysis of HE4
expression in normal and malignant human tissues. Mod Pathol 2006,
19:847–853.
15. Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, Fink D,
Heinzelmann-Schwarz V: No benefit from combining HE4 and CA125 as
ovarian tumor markers in a clinical setting. Gynecol Oncol 2011, 121:487–491.
16. Bolstad N, Oijordsbakken M, Nustad K, Bjerner J: Human epididymis protein
4 reference limits and natural variation in a Nordic reference population.
Tumour Biol 2012, 33:141–148.
doi:10.1186/1477-7819-12-169
Cite this article as: Bie and Zhang: Diagnostic value of serum HE4 in
endometrial cancer: a meta-analysis. World Journal of Surgical Oncology
2014 12:169.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
